Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1
British Journal of Cancer 116, 1027 (11 April 2017). doi:10.1038/bjc.2017.55
Authors: Li Xu, Yuanrun Zhu, Jinjin Shao, Min Chen, Hao Yan, Guanqun Li, Yi Zhu, Zhifei Xu, Bo Yang, Peihua Luo & Qiaojun He
http://ift.tt/2mjvNOI
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου